Topiramate Tablet
Product Images NDC 43063-729

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 43063-729). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063729 Label (43063729)

This is a medication packaging for Topiramate tablets of 100mg strength. It contains 60 tablets for consumption and has an orange color with markings of 124 on it. It has dosage instructions, storage information, and a warning to keep it out of children’s reach. The package also has details such as reorder number, lot number, and an expiration date of 01/2021. The packaging also suggests contacting a doctor in case of side-effects and reporting them to the FDA. There are also barcode and serial number details for tracking purposes. Overall, it contains essential information related to the medication.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 01

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02

This is a graph showing cumulative rates for time to first seizure for two different groups of people taking different amounts of Topamax (Topiramate) medication. The group taking 50mg per day is represented by a dotted line and the group taking 400mg per day is represented by a solid line. The graph shows that the group taking the higher dose of medication experiences a lower rate of seizures over time. The X-axis represents time in days, and the Y-axis represents the cumulative rate of seizures.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03

The text describes the change in the frequency of migraine attacks in a double-blind phase after taking Topamax medication. The medication is available in two dosages, 100 mg/day and 200 mg/day. The average monthly migraine rate increased by 56% compared to the baseline. The asterisks indicate statistical significance.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.